Development of an in vitro assay as correlate of passive immune protection against botulinum neurotoxin to minimize use of whole animal testing

Award Information
Agency:
Department of Defense
Branch
Office for Chemical and Biological Defense
Amount:
$999,988.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
W81XWH-11-C-0085
Agency Tracking Number:
C2-0367
Solicitation Year:
2011
Solicitation Topic Code:
CBD11-109
Solicitation Number:
2011.1
Small Business Information
Electronic BioSciences INC
5754 Pacific Center Blvd Suite 204, San Diego, CA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
129852864
Principal Investigator:
Eric Ervin
Vice President of R&D
(801) 582-0146
ervin@electronicbio.com
Business Contact:
Tracey Wrightson
Director of Operations
(858) 412-1800
twrightson@electronicbio.com
Research Institution:
Stub




Abstract
This Small Business Innovation Research project will develop a non-animal based in vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics. New technologies are currently needed in order to facilitate the development and approval of BoNT vaccines and therapies and reduce the number of vertebrate animals used in medical testing. In Phase 1 of this project, the feasibility of the proposed system was demonstrated. During Phase 2, a complete working prototype will now be built, tested and validated against the standard mouse lethality neutralization (MLN) assay. Electronic BioSciences"proposed system will be capable of monitoring the complete neutralizing mechanism of therapies to all seven BoNT serotypes, making rapid, non-animal based neutralization efficacy testing possible.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government